Transaction DateRecipientSharesTypePriceValue
6th October 2020John L Lamattina46,388Conversion of derivative$0.00
24th August 2020Matthew W Foehr78Open or private sale$110.89$8,649.42
24th August 2020Matthew W Foehr78Exercise of derivative$21.92$1,709.76
21st August 2020Matthew W Foehr790Exercise of derivative$74.42$58,791.80
21st August 2020Matthew W Foehr7,225Exercise of derivative$14.47$104,545.75
21st August 2020Matthew W Foehr7,225Open or private sale$112.88$815,540.66
18th August 2020Todd C Davis50,000Open or private sale$4.99$249,500.00
7th August 2020Todd C Davis30,000Exercise of derivative$0.00
7th July 2020John L Higgins1,777Exercise of derivative$56.26$99,974.02
7th July 2020John L Higgins1,165Exercise of derivative$85.79$99,945.35
Ligand Pharmaceuticalsorporated
Ligand Pharmaceuticalsorporated logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Ligand Pharmaceuticals, Inc. is a biopharmaceutical company. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987.


Ticker: LGND
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 886163
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $115 M (60%)
Inventory, Net: $4 M (-49%)
Other Assets, Current: $5 M (15%)
Assets, Current: $864 M (-23%)
Property, Plant and Equipment, Net: $8 M (9%)
Other Assets, Noncurrent: $6 M (157%)
Assets: $1 B (-16%)
Accounts Payable, Current: $6 M (152%)
Accrued Liabilities, Current: $13 M (0%)
Liabilities, Current: $29 M (72%)
Other Liabilities, Noncurrent: $26 M (17%)
Liabilities: $548 M (-24%)
Common Stock, Value, Issued: $16 Th (-5%)
Common Stock, Shares, Issued: $16 Th (-4%)
Retained Earnings (Accumulated Deficit): $393 M (-1%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (969%)
Stockholders' Equity (Parent): $695 M (0%)
Liabilities and Equity: $1 B (-16%)
Research and Development: $13 M (-48%)
General and Administrative Expenses: $10 M (-47%)
Operating Income/Loss: $7 M (-34%)
Other Income, net: $21 M (59%)
Income before taxes: $28 M (1124%)
Provision for income taxes: $6 M (2303%)
EPS (basic): $1.38 (961%)
EPS (diluted): $1.32 (915%)